The Caris Precision Oncology Alliance leverages the opportunities of big data, artificial intelligence and the collaborative research initiatives of our members to identify predictive and prognostic markers to further advance the integration of molecular profiling into all aspects of cancer care.”
Chadi Nabhan, MD, MBA, FACP
Chairman
Precision Oncology Alliance
The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:
It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers and aids in the promotion of clinical trials, which ultimately feeds back into our system and directly helps patients. This cultivation of combined clinical-genomic data and collaborative research helps the POA and all of its members advance the science of cancer care.
As a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation, Caris Life Sciences (Caris) is helping our POA partners improve cancer care and maximize patient outcomes through advanced diagnostic testing and molecular insights. Caris has a unique combination of expertise, proprietary technologies, clinical testing abilities and a vast library of data that allows Caris and the POA to collaboratively advance precision medicine in ways never before possible.
Resources
*CODEai is not yet available to international members.
The POA is made up of over 80 leading cancer centers and academic institutions, including over 30 NCI-designated comprehensive cancer centers, collaborating to deliver molecular science solutions in an effort to promote clinical trials, deliver combined clinical-genomic data, collaborative research, and publications.
Physicians
Locations
New Patients Annually
Manuscripts in Medical and Scientific Journals and Publications
Abstracts, Posters and Presentations
Submitted Letters of Intent
With support from our POA staff, members meet regularly and focus on research strategies, publication activities and develop protocols within the disease state of interest. These meetings give all members the opportunity to lead discussions and collaborate on best practices and guidelines for clinical trials as well as review the overall implications for patients. Currently, there are 18 disease groups within the POA and registration for all meetings can be found here.
Member investigators often engage with Caris on more specific requests ranging from, but not limited to:
CTRT: Clinical & Translational Research Team
In addition to creating a thought leadership network to develop best practices and guidelines for integrating molecular profiling into patient treatment management, POA members:
Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.
The POA Executive Committee establishes appropriate molecular testing principles.